These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 31264313

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial.
    Sangouni AA, Mohammad Hosseini Azar MR, Alizadeh M.
    Br J Nutr; 2020 Aug 28; 124(4):450-456. PubMed ID: 32312333
    [Abstract] [Full Text] [Related]

  • 4. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F, Adibi P, Hekmatdoost A.
    Br J Nutr; 2015 Sep 14; 114(5):796-803. PubMed ID: 26234526
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Wheat germ improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.
    Salehi-Sahlabadi A, Kord-Varkaneh H, Kocaadam-Bozkurt B, Seraj SS, Alavian SM, Hekmatdoost A.
    Phytother Res; 2022 Nov 14; 36(11):4201-4209. PubMed ID: 35843540
    [Abstract] [Full Text] [Related]

  • 8. The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial.
    Darand M, Darabi Z, Yari Z, Hedayati M, Shahrbaf MA, Khoncheh A, Hosseini-Ahangar B, Alavian SM, Hekmatdoost A.
    Phytother Res; 2019 Sep 14; 33(9):2369-2377. PubMed ID: 31293021
    [Abstract] [Full Text] [Related]

  • 9. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.
    Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A.
    Am J Clin Nutr; 2014 Mar 14; 99(3):535-42. PubMed ID: 24401715
    [Abstract] [Full Text] [Related]

  • 10. The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial.
    Yari Z, Cheraghpour M, Alavian SM, Hedayati M, Eini-Zinab H, Hekmatdoost A.
    Eur J Clin Nutr; 2021 Jan 14; 75(1):99-111. PubMed ID: 32647367
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial.
    Darabi Z, Darand M, Yari Z, Hedayati M, Faghihi A, Agah S, Hekmatdoost A.
    BMC Res Notes; 2019 Feb 15; 12(1):89. PubMed ID: 30767788
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial.
    Darvish Damavandi R, Shidfar F, Najafi M, Janani L, Masoodi M, Akbari-Fakhrabadi M, Dehnad A.
    Phytother Res; 2021 Jun 15; 35(6):3145-3156. PubMed ID: 33880813
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, Socha P.
    J Pediatr; 2015 Jun 15; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L, Bonci E, Di Martino M, Versacci P, Andreoli G, Silvestri LM, Chiesa C.
    Nutr Metab Cardiovasc Dis; 2015 Aug 15; 25(8):734-41. PubMed ID: 26026214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.